202 related articles for article (PubMed ID: 23428290)
1. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.
Yulyana Y; Endaya BB; Ng WH; Guo CM; Hui KM; Lam PY; Ho IA
Stem Cells Dev; 2013 Jul; 22(13):1870-82. PubMed ID: 23428290
[TBL] [Abstract][Full Text] [Related]
2. Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.
Yulyana Y; Tovmasyan A; Ho IA; Sia KC; Newman JP; Ng WH; Guo CM; Hui KM; Batinic-Haberle I; Lam PY
Stem Cell Rev Rep; 2016 Feb; 12(1):140-55. PubMed ID: 26454429
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
4. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
5. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.
Martinez-Quintanilla J; Bhere D; Heidari P; He D; Mahmood U; Shah K
Stem Cells; 2013 Aug; 31(8):1706-14. PubMed ID: 23389839
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
9. DATS sensitizes glioma cells to TRAIL-mediated apoptosis by up-regulation of death receptor 5 via ROS.
Hwang JS; Lee YY; Lee DH; Kwon KH
Food Chem Toxicol; 2017 Aug; 106(Pt A):514-521. PubMed ID: 28571773
[TBL] [Abstract][Full Text] [Related]
10. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
Park SA; Han HR; Ahn S; Ryu CH; Jeun SS
Oncol Rep; 2021 Mar; 45(3):869-878. PubMed ID: 33469674
[TBL] [Abstract][Full Text] [Related]
12. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
13. Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant glioma.
Li M; Sun S; Dangelmajer S; Zhang Q; Wang J; Hu F; Dong F; Kahlert UD; Zhu M; Lei T
Stem Cell Res Ther; 2019 Mar; 10(1):88. PubMed ID: 30867058
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Combination Treatment Effect With TRAIL-secreting Mesenchymal Stem Cells and Compound C Against Glioblastoma.
Han HR; Park SA; Ahn S; Jeun SS; Ryu CH
Anticancer Res; 2019 Dec; 39(12):6635-6643. PubMed ID: 31810928
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma.
Choi SA; Hwang SK; Wang KC; Cho BK; Phi JH; Lee JY; Jung HW; Lee DH; Kim SK
Neuro Oncol; 2011 Jan; 13(1):61-9. PubMed ID: 21062796
[TBL] [Abstract][Full Text] [Related]
16. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
17. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
Sasportas LS; Kasmieh R; Wakimoto H; Hingtgen S; van de Water JA; Mohapatra G; Figueiredo JL; Martuza RL; Weissleder R; Shah K
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4822-7. PubMed ID: 19264968
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma.
Ryu CH; Park KY; Kim SM; Jeong CH; Woo JS; Hou Y; Jeun SS
Biochem Biophys Res Commun; 2012 May; 421(3):585-90. PubMed ID: 22525671
[TBL] [Abstract][Full Text] [Related]
19. BNIP3 acts as transcriptional repressor of death receptor-5 expression and prevents TRAIL-induced cell death in gliomas.
Burton TR; Henson ES; Azad MB; Brown M; Eisenstat DD; Gibson SB
Cell Death Dis; 2013 Apr; 4(4):e587. PubMed ID: 23579274
[TBL] [Abstract][Full Text] [Related]
20. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
